Our open innovation strategy is designed to promote change beyond GSK by sharing expertise, resources, intellectual property and know-how with external researchers and the scientific community.
Our previous focus was on diseases of the developing world, such as malaria, tuberculosis and parasitic infections and, we are now adapting open innovation models to apply to other areas of great medical need and scientific challenge including infectious, autoimmune disease, immuno-oncology and rare diseases.
Our 30-year quest to develop a malaria vaccine
We’ve been fighting malaria on all fronts for the past 100 years - and are now on the verge of developing the first malaria vaccine - as well as signing a five-year partnership with Comic Relief to provide on-the-ground support in some of the worst affected areas.
Diseases of the developing world
To achieve sustainable improvements in access to essential care and medicines in the developing world, we need to have a dedicated strategy devoted to it
Stevenage bioscience hub
The Stevenage Bioscience Catalyst campus is a major hub for early-stage biotechnology companies
Find out more
Our medicines and vaccines currently in development across three stages: phase I, phase II and phase III
How we discover new medicines
Researching and developing a new medicine typically goes through several stages from laboratory to patient
How we discover new vaccines
Our vaccines R&D is focused on discovering prophylactic and therapeutic vaccines to protect people against infectious diseases, cancers and chronic disorders.
Consumer healthcare research
GSK products are built around science, and it is this innovation that is vital to our Consumer Healthcare business